About Cellix Bio
Cellix Bio is a company based in Hyderabad (India) founded in 2014 by Mahesh Kandula. Cellix Bio has raised $4.64 million across 5 funding rounds from investors including V ClinBio, Jan Pieter Werkman and Deepak Maheshwari. Cellix Bio operates in a competitive market with competitors including Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.
- Headquarter Hyderabad, India
- Founders Mahesh Kandula
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cellix Bio Private Limited
- Date of Incorporation 21 May, 2014
- Jurisdiction Tirumalagiri, Telangana, India
-
Annual Revenue
$14.21 K (USD)6.93as on Mar 31, 2021
-
Net Profit
-$63.33 K (USD)-26.17as on Mar 31, 2021
-
EBITDA
-$63.07 K (USD)-56.83as on Mar 31, 2021
-
Total Equity Funding
$4.64 M (USD)
in 5 rounds
-
Latest Funding Round
$493.47 K (USD), Angel Round
Jun 07, 2021
-
Investors
V ClinBio
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cellix Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Cellix Bio
Cellix Bio has successfully raised a total of $4.64M across 5 strategic funding rounds. The most recent funding activity was a Angel Round of $493.47 thousand completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellix Bio
Cellix Bio has secured backing from 9 investors, including angel and institutional investors. Prominent investors backing the company include V ClinBio, Jan Pieter Werkman and Deepak Maheshwari.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
V ClinBio provides drug discovery and development services for small and large molecules.
|
Locked | Locked | Locked | |
|
Develops innovative therapeutic technologies to address various medical conditions effectively.
|
Locked | Locked | Locked | |
|
JP
Jan Pieter Werkman |
-
|
Locked | Locked | Locked |
Investor details for Cellix Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellix Bio
Investment portfolio details for Cellix Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellix Bio
Detailed financials for Cellix Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellix Bio Comparisons
Peer comparison for Cellix Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellix Bio
Cellix Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An agentic AI platform is developed for biomedical research insights.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
AI-based technology is used for recombinant protein production in therapeutics.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
|
| Locked | Locked | Locked |
AI platform used for extracting antibody data from scientific papers.
|
Detailed competitors of Cellix Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellix Bio
Complete news archive for Cellix Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellix Bio
Cellix Bio was founded in 2014 and raised its 1st funding round 4 years after it was founded.
Cellix Bio is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Mahesh Kandula is the current CEO of Cellix Bio. They have also founded this company.
Cellix Bio is a funded company, having raised a total of $4.64M across 5 funding rounds to date.
Annual revenue of Cellix Bio is $14.21K as on Mar 31, 2021.
Cellix was founded in 2014 in Hyderabad, India, within the biotechnology sector. An AI-driven platform is operated for drug discovery and development focused on neurological, inflammatory, and metabolic diseases. The proprietary Synergix AI is employed to design novel molecular entities exhibiting synergistic pharmacological effects, thereby streamlining the identification of drug candidates. A range of therapeutic assets is maintained across these disease areas.
Cellix Bio's top competitors include Owkin, Formation Bio and XtalPi.
Cellix Bio has 9 investors. Key investors include V ClinBio, Jan Pieter Werkman, Deepak Maheshwari, Paresh Dattatraya Sukthankar, and Pratapreddy Lingareddy Gaddam.
The valuation of Cellix Bio is $188.21M as of Jun 2021.